SKYEPHARMA PLC
Form 6-K
August 11, 2006

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of August, 2006

SkyePharma PLC

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F X Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No X

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-
_____

For Immediate Release

SkyePharma PLC

Statement Regarding Recent Share Price Movement

LONDON, UK, 11 August 2006 -- SkyePharma PLC (Nasdaq: SKYE; LSE: SKP) notes the recent decl
confirms that it is not aware of any fundamental reason for this decline.

Frank Condella, SkyePharma's Chief Executive Officer, said: "We are disappointed by the fal
weeks. We are continuing our efforts to deliver on the strategy outlined earlier this year
out-license Flutiform outside the US and we remain confident that we will be able to achieve th
support of our major shareholders who have maintained their shareholdings during this period."

Earlier this year the Board decided to divest the injectables unit, a stand-alone operation w
manufacture in San Diego. UBS, the investment bank appointed for this disposal, is managing th
with interested parties and also with certain companies that have expressed an interest in DepoB
The Company is progressing with several options, all of which are geared towards bringing in ca
The Company continues to expect to complete a transaction before the end of the year.

For key pipeline products, the Phase III trials of Flutiform are proceeding and remain on tra
this key product with the US Food & Drug Administration ("FDA") in the second half of 2007. Sk
of AstraZeneca's combination asthma product Symbicort® and is encouraged by the speed wit
approved, increasing confidence that the Company's previous expectation of a US market launch f
possibly conservative. Having now appointed Kos Pharmaceuticals as the licensee for Flutifo
engaged in late-stage negotiations for other key markets.

With its partner Novartis, the Company has successfully completed modifications to its d
mishandling that it is hoped will allow Foradil® Certihaler to be returned to the market in
USA. The modified product is currently being reviewed by the FDA and a decision is expected befor

In addition to the above, the Company is cognisant of the longer term requirement to grow the bus
a number of early-stage projects under active consideration. Following a planning meeting
expects to be in a position to outline its strategic plans in more detail.

For further information please contact:

SkyePharma PLC	**+44 207 491 1777**
Frank Condella, Chief Executive Officer	
Peter Laing, Director of Corporate Communications	**44 207 491 5124**
Sandra Haughton, US Investor Relations	**+1 212 753 5780**
Buchanan Communications	**+44 207 466 5000**
Tim Anderson / Mark Court / Rebecca Skye Dietrich	

About SkyePharma

SkyePharma PLC develops pharmaceutical products benefiting from world-leading drug delivery te
and more effective drug formulations. There are now twelve approved products incorporating Skye
oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabi
www.skyepharma.com.

*Certain statements in this news release are forward-looking statements and are made in reliance
U.S. Private Securities Litigation Act of 1995. Although SkyePharma believes that the expectatio
statements are reasonable, it can give no assurance that these expectations will materialize. B
risks and uncertainties, actual results may vary significantly from those expressed or impli
based upon a number of factors, which are described in SkyePharma's 20-F and other documents on
cause differences between actual results and those implied by the forward-looking statements c
without limitation, risks related to the development of new products, risks related to obtainin
for existing, new or expanded indications of existing and new products, risks related to SkyePh*

on a large scale or at all, risks related to SkyePharma's and its marketing partners' ability maintain or expand market share in the face of changes in customer requirements, competition an to regulatory compliance, the risk of product liability claims, risks related to the ownership risks related to SkyePharma's ability to manage growth. SkyePharma undertakes no obliga forward-looking statement to reflect events or circumstances after the date of this release.

END

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SkyePharma PLC

By: /s/ Douglas Parkhill

Name: Douglas Parkhill
Title: Company Secretary

Date: August 11, 2006